This company listing is no longer active
4D pharma (4DY) Stock Overview
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
4DY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
4D pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.38 |
| 52 Week High | UK£0.99 |
| 52 Week Low | UK£0.31 |
| Beta | 3.19 |
| 1 Month Change | 0% |
| 3 Month Change | 0.94% |
| 1 Year Change | n/a |
| 3 Year Change | -53.86% |
| 5 Year Change | -89.12% |
| Change since IPO | -95.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 0.3% |
| 1Y | n/a | -11.3% | 14.6% |
Return vs Industry: Insufficient data to determine how 4DY performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 4DY performed against the German Market.
Price Volatility
| 4DY volatility | |
|---|---|
| 4DY Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4DY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4DY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 106 | Duncan Peyton | www.4dpharmaplc.com |
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn’s disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis.
4D pharma plc Fundamentals Summary
| 4DY fundamental statistics | |
|---|---|
| Market cap | €35.41m |
| Earnings (TTM) | -€31.95m |
| Revenue (TTM) | €718.36k |
Is 4DY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DY income statement (TTM) | |
|---|---|
| Revenue | US$718.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$718.00k |
| Other Expenses | US$32.66m |
| Earnings | -US$31.94m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,448.19% |
| Debt/Equity Ratio | 36.5% |
How did 4DY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/28 00:03 |
| End of Day Share Price | 2022/05/31 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
4D pharma plc is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Taylor Feehley | Chardan Capital Markets, LLC |